z-logo
Premium
Imeglimin increases glucose‐dependent insulin secretion and improves β‐cell function in patients with type 2 diabetes
Author(s) -
Pacini G.,
Mari A.,
Fouqueray P.,
Bolze S.,
Roden M.
Publication year - 2015
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12452
Subject(s) - medicine , insulin , endocrinology , type 2 diabetes , diabetes mellitus , metformin , area under the curve , placebo , c peptide , alternative medicine , pathology
Aims To assess the glucose‐stimulated insulin secretion effect of imeglimin in patients with type 2 diabetes. Methods We conducted a double‐blind, randomized, placebo‐controlled study in 33 patients with type 2 diabetes [glycated haemoglobin 6.8 ± 0.1% (51 mmol/mol)], who were drug‐naïve or withdrawn from their previous metformin monotherapy for 2 weeks and received imeglimin 1500 mg twice daily or placebo for 1 week. Glucose‐stimulated insulin secretion was assessed using a hyperglycaemic clamp. The primary endpoint was insulin secretion as defined by total insulin response [incremental area under the curve ( iAUC ) 0–45 min ] and insulin secretion rate ( ISR ) calculated from C‐peptide deconvolution. β‐cell glucose sensitivity at steady state (second phase: 25–45 min), hepatic insulin extraction and insulin clearance were also calculated. Results Imeglimin treatment for 7 days raised the insulin secretory response to glucose by +112% ( iAUC 0‐45 , p = 0.035), first‐phase ISR by +110% (p = 0.034) and second‐phase ISR by +29% (p = 0.031). Imeglimin improved β‐cell glucose sensitivity by +36% (p = 0.034) and tended to decrease hepatic insulin extraction (−13%; p = 0.056). Imeglimin did not affect glucagon secretion. Conclusions In patients with type 2 diabetes, imeglimin improves β‐cell function, which may contribute to the glucose‐lowering effect observed with imeglimin in clinical trials.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here